Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Basal Cell 3Pancreatic Neoplasms 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Telangiectasis 1Skin Neoplasms 1Rosacea 1Prostatic Neoplasms 1Precancerous Conditions 1Port-Wine Stain 1Pancreatic Intraductal Neoplasms 1Non-melanoma Skin Cancer 1Nevus, Pigmented 1Nasopharyngeal Neoplasms 1Mixed Tumor, Malignant 1Melanoma 1Lung Neoplasms 1Keratosis, Seborrheic 1Keratosis 1Hemangioma 1Glioma 1Carcinoma, Transitional Cell 1Carcinoma 1Barrett Esophagus 1

Interventions

Temozolomide 156Bevacizumab 69Radiotherapy 61Magnetic Resonance Spectroscopy 59Irinotecan 31Surgical Procedures, Operative 23Radiation 23Carboplatin 23Specimen Handling 20Carmustine 20Nivolumab 19Biopsy 17Lomustine 15Aminolevulinic Acid 15Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12pembrolizumab 12Radiosurgery 12Erlotinib Hydrochloride 12fluorodopa F 18 11Topotecan 11Everolimus 11Blood Specimen Collection 11X-Rays 10IL13-PE38 10dabrafenib 9Etoposide 9ribociclib 8poly ICLC 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioma × Tomography, Optical Coherence × Clear all
NCT05859334 2026-05-13

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡